Handelsbanken Fonder Ab Horizon Therapeutics Public LTD CO Transaction History

Handelsbanken Fonder Ab

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 19, 2023	BUY	$98.98 - $115.74 $46,520 - $54,397	470 Added 0.68%	69,475 $8.04 Million
Q2 2023 Aug 02, 2023	BUY	$96.34 - $112.38 $2.27 Million - $2.65 Million	23,570 Added 51.88%	69,005 $7.1 Million
Q1 2023 Apr 28, 2023	SELL	$107.32 - $113.5 $15 Million - $15.9 Million	-139,685 Reduced 75.46%	45,435 $4.96 Million
Q4 2022 Feb 07, 2023	BUY	$62.39 - $113.8 $6.7 Million - $12.2 Million	107,443 Added 138.32%	185,120 $21.1 Million
Q3 2022 Oct 27, 2022	BUY	$58.92 - $84.67 $23,391 - $33,613	397 Added 0.51%	77,677 $4.81 Million

Q2 2022 Aug 03, 2022	BUY	$79.4 - $116.36 $3.83 Million - $5.61 Million	48,180 Added 165.57%	77,280 $6.16 Million
Q1 2022 May 11, 2022	BUY	$86.42 - $109.81 $2.51 Million - $3.2 Million	29,100 New	29,100 $3.06 Million
Q3 2021 Nov 10, 2021	SELL	$91.91 - $110.37 $3.45 Million - $4.14 Million	-37,520 Closed	0 $0
Q2 2021 Aug 03, 2021	BUY	$86.24 - $95.92 $3.24 Million - $3.6 Million	37,520 New	37,520 $3.51 Million
Q1 2021 Apr 29, 2021	SELL	$71.83 - $95.48 $2.92 Million - $3.88 Million	-40,620 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$67.0 - $84.39 $2.72 Million - $3.43 Million	40,620 New	40,620 $2.97 Million

2.07M

20K

Ticker HZNP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 230,384,000
Description
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.